Skip to content

Study · In vitro (cells) · 2020

10 results

Humanin attenuates palmitate-induced hepatic lipid accumulation and insulin resistance via AMPK-mediated suppression of the mTOR pathway.

Kwon C, Sun JL, Jeong JH, Jung TW

Biochemical and biophysical research communications31 Mar 2020Cited by 33 (Europe PMC)

PMID32245619 (opens in a new tab)DOI10.1016/j.bbrc.2020.03.128 (opens in a new tab)PepBankPUB-32245619
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    Humanin treatment ameliorated palmitate-induced lipid accumulation in hepatocytes in a dose-dependent manner.

    In plain wordsIn liver cells, humanin reduced fat build-up caused by palmitate, with larger effects at higher doses.

    Peptide
    Humanin
    Outcome
    DecreasePalmitate-induced lipid accumulation
    Study

    n: not reported in source

    palmitate-treated hepatocytes
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that HN-treatment ameliorated palmitate-induced lipid accumulation, expression of lipogenesis-associated genes (processed SREBP1, FAS, and SCD1), cell death, and caspase 3 activity in hepatocytes in a dose-dependent manner.
    1 context sentence
    Summary · context
    This study aim was to investigate effects of HN on lipid accumulation in the hepatocytes and insulin signaling, and explore the underlying mechanisms.
  2. 02LabIn vitro (cells)Mechanism

    Humanin treatment reduced palmitate-induced expression of processed SREBP1 in hepatocytes in a dose-dependent manner.

    In plain wordsIn liver cells, humanin lowered a fat-making protein called SREBP1, with larger effects at higher doses.

    Peptide
    Humanin
    Outcome
    DecreaseProcessed SREBP1 expression
    Study

    n: not reported in source

    palmitate-treated hepatocytes
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that HN-treatment ameliorated palmitate-induced lipid accumulation, expression of lipogenesis-associated genes (processed SREBP1, FAS, and SCD1), cell death, and caspase 3 activity in hepatocytes in a dose-dependent manner.
    1 context sentence
    Summary · context
    This study aim was to investigate effects of HN on lipid accumulation in the hepatocytes and insulin signaling, and explore the underlying mechanisms.
  3. 03LabIn vitro (cells)Mechanism

    Humanin treatment reduced palmitate-induced expression of FAS in hepatocytes in a dose-dependent manner.

    In plain wordsIn liver cells, humanin lowered a fat-making gene called FAS, with larger effects at higher doses.

    Peptide
    Humanin
    Outcome
    DecreaseFAS expression
    Study

    n: not reported in source

    palmitate-treated hepatocytes
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that HN-treatment ameliorated palmitate-induced lipid accumulation, expression of lipogenesis-associated genes (processed SREBP1, FAS, and SCD1), cell death, and caspase 3 activity in hepatocytes in a dose-dependent manner.
    1 context sentence
    Summary · context
    This study aim was to investigate effects of HN on lipid accumulation in the hepatocytes and insulin signaling, and explore the underlying mechanisms.
  4. 04LabIn vitro (cells)Mechanism

    Humanin treatment reduced palmitate-induced expression of SCD1 in hepatocytes in a dose-dependent manner.

    In plain wordsIn liver cells, humanin lowered a fat-making gene called SCD1, with larger effects at higher doses.

    Peptide
    Humanin
    Outcome
    DecreaseSCD1 expression
    Study

    n: not reported in source

    palmitate-treated hepatocytes
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that HN-treatment ameliorated palmitate-induced lipid accumulation, expression of lipogenesis-associated genes (processed SREBP1, FAS, and SCD1), cell death, and caspase 3 activity in hepatocytes in a dose-dependent manner.
    1 context sentence
    Summary · context
    This study aim was to investigate effects of HN on lipid accumulation in the hepatocytes and insulin signaling, and explore the underlying mechanisms.
  5. 05LabIn vitro (cells)Efficacy outcome

    Humanin treatment reduced palmitate-induced cell death in hepatocytes in a dose-dependent manner.

    In plain wordsIn liver cells, humanin reduced cell death caused by palmitate, with larger effects at higher doses.

    Peptide
    Humanin
    Outcome
    DecreasePalmitate-induced cell death
    Study

    n: not reported in source

    palmitate-treated hepatocytes
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that HN-treatment ameliorated palmitate-induced lipid accumulation, expression of lipogenesis-associated genes (processed SREBP1, FAS, and SCD1), cell death, and caspase 3 activity in hepatocytes in a dose-dependent manner.
    1 context sentence
    Summary · context
    This study aim was to investigate effects of HN on lipid accumulation in the hepatocytes and insulin signaling, and explore the underlying mechanisms.
  6. 06LabIn vitro (cells)Mechanism

    Humanin treatment reduced palmitate-induced caspase 3 activity in hepatocytes in a dose-dependent manner.

    In plain wordsIn liver cells, humanin lowered a cell-death enzyme activity, with larger effects at higher doses.

    Peptide
    Humanin
    Outcome
    DecreaseCaspase 3 activity
    Study

    n: not reported in source

    palmitate-treated hepatocytes
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that HN-treatment ameliorated palmitate-induced lipid accumulation, expression of lipogenesis-associated genes (processed SREBP1, FAS, and SCD1), cell death, and caspase 3 activity in hepatocytes in a dose-dependent manner.
    1 context sentence
    Summary · context
    This study aim was to investigate effects of HN on lipid accumulation in the hepatocytes and insulin signaling, and explore the underlying mechanisms.
  7. 07LabIn vitro (cells)Efficacy outcome

    Humanin attenuated palmitate-induced impairment of insulin signaling in hepatocytes.

    In plain wordsIn liver cells, humanin eased the harm that palmitate did to insulin signalling.

    Peptide
    Humanin
    Outcome
    IncreaseInsulin signaling in palmitate-treated hepatocytes
    Study

    n: not reported in source

    palmitate-treated hepatocytes
    Outcome group
    Glycemic control · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Additionally, HN attenuated palmitate-induced impairment of insulin signaling.
    1 context sentence
    Summary · context
    This study aim was to investigate effects of HN on lipid accumulation in the hepatocytes and insulin signaling, and explore the underlying mechanisms.
  8. 08LabIn vitro (cells)Mechanism

    Humanin enhanced AMPK phosphorylation in hepatocytes.

    In plain wordsIn liver cells, humanin increased activation of AMPK.

    Peptide
    Humanin
    Outcome
    IncreaseAMPK phosphorylation
    Study

    n: not reported in source

    palmitate-treated hepatocytes
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HN enhanced AMPK phosphorylation, whereas it suppressed palmitate-induced phosphorylation of mTOR.
    1 context sentence
    Summary · context
    This study aim was to investigate effects of HN on lipid accumulation in the hepatocytes and insulin signaling, and explore the underlying mechanisms.
  9. 09LabIn vitro (cells)Mechanism

    Humanin suppressed palmitate-induced phosphorylation of mTOR in hepatocytes.

    In plain wordsIn liver cells, humanin reduced palmitate-driven activation of mTOR.

    Peptide
    Humanin
    Outcome
    DecreasePalmitate-induced mTOR phosphorylation
    Study

    n: not reported in source

    palmitate-treated hepatocytes
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HN enhanced AMPK phosphorylation, whereas it suppressed palmitate-induced phosphorylation of mTOR.
    1 context sentence
    Summary · context
    This study aim was to investigate effects of HN on lipid accumulation in the hepatocytes and insulin signaling, and explore the underlying mechanisms.

Studies that did not test the peptide alone1

In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Humanin.

  1. 10LabNot a test of Humanin aloneIn vitro (cells)Mechanism

    AMPK knockdown by siRNA neutralized the effects of humanin on palmitic acid-treated hepatocytes.

    In plain wordsIn liver cells, switching off AMPK removed the effects of humanin on cells treated with palmitic acid.

    Peptide
    Humanin
    Outcome
    No significant changeHumanin effects after AMPK knockdown
    Study

    n: not reported in source

    palmitate-treated hepatocytes
    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    AMPK knockdown by siRNA neutralized the effects of HN on palmitic acid-treated hepatocytes.
    1 context sentence
    Summary · context
    This study aim was to investigate effects of HN on lipid accumulation in the hepatocytes and insulin signaling, and explore the underlying mechanisms.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.